Beyond Air (NASDAQ:XAIR) released its earnings results on Wednesday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.07, Fidelity Earnings reports.
XAIR opened at $5.25 on Friday. The company has a quick ratio of 7.99, a current ratio of 7.99 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $107.56 million, a PE ratio of -3.78 and a beta of -0.57. The company’s fifty day moving average is $5.32. Beyond Air has a fifty-two week low of $4.62 and a fifty-two week high of $7.96.
A number of analysts have recently issued reports on the stock. Truist began coverage on shares of Beyond Air in a research note on Wednesday, April 28th. They issued a “buy” rating and a $12.00 price objective for the company. Truist Securities assumed coverage on Beyond Air in a report on Wednesday, April 28th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Zacks Investment Research raised Beyond Air from a “sell” rating to a “hold” rating in a research note on Wednesday, April 14th.
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc and changed its name to Beyond Air, Inc in June 2019.
Featured Article: Investing strategies using the yield curve
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.